We would like to get input from the LOINC community regarding the FLT3-ITD test mapping granularity.
We have a local test reporting FLT3-ITD mutation detected and another local test reporting the FLT3-ITD mutation detected in exon 14 and 15 (1). We know that FLT3-ITD mutation can be detected in exon 11& 12 (2) from publications. Should we create 2 local LOINC codes* for exon specific and non-specific tests?
* LOINC has no office code for FLT3-ITD test at this moment yet.
(1) Detection of FLT3 Oncogene Mutations in Acute Myeloid Leukemia Using Conformation Sensitive Gel Electrophoresis